Navigation Links
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
Date:10/27/2008

linic."

Dr Andrew Cuthbertson, Director of R&D at CSL said, "The G-CSF inflammatory disease project is an excellent example of the strength of Australian medical research. We look forward to a continuing collaboration with our academic colleagues as we take this program into early stage development."

About MuriGen Therapeutics

MuriGen Therapeutics is an Australian-based drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research and four of its leading scientists. MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia. By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients. Further information about MuriGen Therapeutics can be found at http://www.murigen.com.au

About WEHI

The Walter and Eliza Hall Institute of Medical Research (WEHI) is one of the world's leading medical research centres. WEHI's international reputation has been built upon major contributions to immunology, haematology, cancer, malaria and autoimmune diseases, including diabetes, multiple sclerosis, coeliac disease and rheumatoid arthritis. Over many decades, advances and discoveries in these areas have led to significant benefits for patients throughout the world. WEHI is in the front line of the biotechnology revolution, using advances in genetics, bioinformatics and structural biology to help develop individualised therapies and more effective drugs. Further information about WEHI can be found at http://www.wehi.edu.au

Further information:

Dr Nick Samaras

Chief Executiv
'/>"/>

SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VaxGen Restructures Board of Directors
2. Genta Restructures Operations to Focus on Priority Initiatives
3. Progen Restructures Manufacturing and Drug Discovery Divisions
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. CME LLC Restructures, Announces Its New Executive Management Team
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
(Date:11/18/2014)... SAN BRUNO, Calif. , Nov. 18, 2014 ... is a platinum sponsor of the 10th Annual World Stem ... and regenerative medicine stakeholders. The 2014 World Stem Cell Summit ... San Antonio, Texas . ... the discovery and development of lifesaving cures and therapies, convening ...
(Date:11/18/2014)... 17, 2014 Cirrascale Corporation ... blade-based and rackmount computing infrastructure, today announced it ... accelerator throughout its GPU-enabled blade server and high-performance ... company’s latest proprietary 80-lane Gen3 PCIe switch-enabled risers, ... Tesla K80 dual-GPU accelerator cards in a single ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... 12 Odyssey Thera, Inc.,announced today that the ... No. 7,306,914, entitled "Protein-fragment Complementation,Assays (PCA) in whole ... infectious disease and gene therapy." This is the,twelfth ... The patent describes a method for detecting protein-protein,interactions ...
... "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of ... First Modules due Before ... ARPN) announced today the enrolment and dosing of the first ... the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) / healthcare-associated ...
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
(Date:11/3/2014)... -- Research and Markets has announced the addition ... and Companies" to their offering. This ... have already started to play an important role in the ... old fashioned bone marrow transplants. Role of cells in drug ... a part of medical practice. Stem cells are ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
... lobe dementia ,Frontal lobe dementia (Frontotemporal Dementia, FTD) ... is the form of dementia that occurs most frequently in ... in the frontal lobe where large numbers of brain cells ... part of the brain and constitutes about 30% of the ...
... J. Craig Venter, Energy Bioscience Institute,s Chris Somerville ... Department of Energy Joint Genome Institute (DOE JGI) ... March 25-27, 2009 in Walnut Creek, Calif. ... of renewable energy strategies, biomass conversion to biofuels, ...
... GAINESVILLE, Fla. Older, active people who have a drink ... according to a report today from a University of Florida ... and Drugs . Although people 50 or older in ... they performed worse on special tests after having moderate amounts ...
Cached Biology News:Blood test predicts chance of dementia 2Venter, Somerville and Church highlight DOE/JGI genomics of energy and environment meeting 2After a few drinks, older adults more impaired than they think 2After a few drinks, older adults more impaired than they think 3
... 48° Fixed Angle Polypropylene Rotor ... Series, IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. ... quiet operation. /MP4, ,EXCLUSIVE polypropylene rotor ... can be repeatedly autoclaved. Polypropylene ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... The Xcise is a powerful technology ... throughput proteome analysis. High quality sample ... untrained user. , The Xcise is a ... for high throughput proteome analysis. It combines ...
Extra Large bottle for hybridization 300 x 70mm...
Biology Products: